Protein networking in bladder cancer: Immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium

Histology and Histopathology

Volumn 22, Issue 4-6, 2007, Pages 349-363

  Røtterud, Ranveig ^a   Fossa S D ^b   Nesland, J M ^b  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Bladder; Carcinoma; FGFR3; Immunohistochemistry; KAI1; PTEN

Indexed keywords

CD82 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 3; P21RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAS PROTEIN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; PROTEIN P21; PTEN PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; BONE METASTASIS; BRAIN METASTASIS; BREAST METASTASIS; CANCER INVASION; CELL MEMBRANE; CELL NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GASTROINTESTINAL DISEASE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PENIS DISEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; SKIN METASTASIS; TISSUE DISTRIBUTION; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; UPREGULATION; UROTHELIUM; VAGINA DISEASE; ADENOCARCINOMA; ADOLESCENT; BLADDER TUMOR; ENZYME IMMUNOASSAY; HISTOLOGY; METABOLISM; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KANGAI-1 PROTEIN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; ONCOGENE PROTEIN P21(RAS); PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 33947493600     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Adjei A.A. (2001). Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer Inst. 93, 1062-1074.
2. Agnantis N.J., Constantinidou A., Poulios C., Pintzas A., Kakkanas A. and Spandidos D.A. (1990). Immunohistochemical study of the ras oncogene expression in human bladder endoscopy specimens. Eur. J. Surg. Oncol. 16, 153-160.
3. Aveyard J.S., Skilleter A., Habuchi T. and Knowles M.A. (1999). Somatic mutation of PTEN in bladder caminoma. Br. J. Cancer 80, 904-908.
4. Billerey C., Chopin D., Aubriot-Lorton M.H., Ricol D., Gil-Diez-de-Medina S., Van Rhijn B., Bralet M.P., Lefrere-Belda M.A., Lahaye J.B., Abbou C.C., Bonaventure J., Zafrani E.S., van der Kwast T., Thiery J.P. and Radvanyi F. (2001). Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol. 158, 1955-1959.
5. Bjorge J.D., Chan T.O., Antczak M., Kung H.J. and Fujita D.J. (1990). Activated type I phosphatidylinositol kinase is associated with the epidermal growth factor (EGF) receptor following EGF stimulation. Proc. Natl. Acad. Sci. USA 87, 3816-3820.
6. Bos J.L. (1989). Ras oncogenes in human cancer: a review. Cancer Res. 49, 4682-4689.
7. Brandau S. and Bohle A. (2001). Bladder cancer. I. Molecular and genetic basis of carcinogenesis. Eur. Urol. 39, 491-497.
8. Burchill S.A., Neal D.E and Lunec J. (1994). Frequency of H-ras mutations in human bladder cancer detected by direct sequencing. Br. J. Urol. 73, 516-521.
9. Cairns P., Evron E., Okami K., Halachmi N., Esteller M., Herman J.G., Bose S., Wang S.I., Parsons R. and Sidransky D. (1998). Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 16, 3215-3218.
10. Cantley L.C. and Neel B.G. (1999). New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA 96, 4240-4245.
11. Cappellen D., De Oliveira C., Ricol D., de Medina S., Bourdin J., Sastre-Garau X., Chopin D., Thiery J.P. and Radvanyi F. (1999). Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 23, 18-20.
12. Cattan N., Saison-Behmoaras T., Mari B., Mazeau C., Amiel J.L., Rossi B. and Gioanni J. (2000). Screening of human bladder carcinomas for the presence of Ha-ras codon 12 mutation. Oncol. Rep. 7, 497-500.
13. Chan T.O., Rodeck U., Chan A.M., Kimmelman A.C., Rittenhouse S.E., Panayotou G. and Tsichlis P.N. (2002). Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell 1, 181-191.
14. Chang E.H., Furth M.E., Scolnick E.M. and Lowy D.R. (1982). Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature 297, 479-483.
15. Chesa P.G., Rettig W.J., Melamed M.R., Old L.J. and Niman H.L. (1987). Expression of p21ras in normal and malignant human tissues: lack of association with proliferation and malignancy. Proc. Natl. Acad. Sci. USA 84, 3234-3238.
16. Chow N.H., Chan S.H., Tzai T.S., Ho C.L. and Liu H.S. (2001). Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin. Cancer Res. 7, 1957-1962.
17. Davies M.A., Kim S.J., Parikh N.U., Dong Z., Bucana C.D. and Gallick G.E. (2002). Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin. Cancer Res. 8, 1904-1914.
18. DeFeo D., Gonda M.A., Young H.A., Chang E.H., Lowy D.R., Scolnick E.M. and Ellis R.W. (1981). Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus. Proc. Natl. Acad. Sci. USA 78, 3328-3332.
19. Dong J.T., Lamb P.W., Rinker-Schaeffer C.W., Vukanovic J., Ichikawa T., Isaacs J.T. and Barrett J.C. (1995). KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268, 884-886.
20. Dunn T.L., Seymour G.J., Gardiner R.A., Strutton G.M. and Lavin M.F. (1988). Immunocytochemical demonstration of p21ras in normal and transitional cell carcinoma urothelium. J. Pathol. 156, 59-65.
21. Ehrhardt A., Ehrhardt G.R., Guo X. and Schrader J.W. (2002). Ras and relatives - job sharing and networking keep an old family together. Exp. Hematol. 30, 1089-1106.
22. Fearon E.R., Feinberg A.P., Hamilton S.H. and Vogelstein B. (1985). Loss of genes on the short arm of chromosome 11 in bladder cancer. Nature 318, 377-380.
23. Furth M.E., Aldrich T.H. and Cordon-Cardo C. (1987). Expression of ras proto-oncogene proteins in normal human tissues. Oncogene 1, 47-58.
24. Gomez-Roman J.J., Saenz P., Molina M., Cuevas G.J., Escuredo K., Santa C.S., Junquera C., Simon L., Martinez A., Gutierrez Banos J.L., Lopez-Brea M., Esparza C. and Val-Bernal J.F. (2005). Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin. Cancer Res. 11, 459-465.
25. Gu J., Tamura M. and Yamada K.M. (1998). Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J. Cell Biol. 143, 1375-1383.
26. Guo X., Friess H., Graber H.U., Kashiwagi M., Zimmermann A., Korc M. and Buchler M.W. (1996). KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res. 56, 4876-4880.
27. Gusterson B., Cowley G., Smith J.A. and Ozanne B. (1984). Cellular localisation of human epidermal growth factor receptor. Cell Biol. Int. Rep. 8, 649-658.
28. Hamilton L.M., Torres-Lozano C., Puddicombe S.M., Richter A., Kimber I., Dearman R.J., Vrugt B., Aalbers R., Holgate S.T., Djukanovic R., Wilson S.J. and Davies D.E. (2003). The role of the epidermal growth factor receptor in sustaining neutrophil inflammation in severe asthma. Clin. Exp. Allergy 33, 233-240.
29. Hermanek P. and Sobin L.H. (1987). Urological Tumours. In TNM Classification of Malignant Tumours. International Union Against Cancer (UICC)). pp 121-144.
30. Huang C.L., Taki T., Adachi M., Yagita M., Sawada S., Takabayashi A., Inufusa H., Yoshie O. and Miyake M. (1997). MRP-1/CD9 and KAI1/CD82 expression in normal and various cancer tissues. Int. J. Oncol. 11, 1045-1051.
31. Hughes S.E. (1997). Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J. Histochem. Cytochem. 45, 1005-1019.
32. Hwang P.H., Yi H.K., Kim D.S., Nam S.Y., Kim J.S. and Lee D.Y. (2001). Suppression of tumorigenicity and metastasis in B16F10 cells by PTEN/ MMAC1/TEP1 gene. Cancer Lett. 172, 83-91.
33. Ioachim E., Charchanti A., Stavropoulos N.E., Skopelitou A., Athanassiou E.D. and Agnantis N.J. (2000). Immunohistochemical expression of retinoblastoma gene product (Rb), p53 protein, MDM2, c-erbB-2, HLA-DR and proliferation indices in human urinary bladder carcinoma. Histol. Histopathol. 15, 721-727.
34. Jimenez R.E., Hussain M., Bianco F.-J.J., Vaishampayan U., Tabazcka P., Sakr W.A., Pontes J.E., Wood D.-P.J. and Grignon D.J. (2001). Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin. Cancer Res. 7, 2440-2447.
35. Kim I., Moon S., Yu K., Kim U. and Koh G.Y. (2001). A novel fibroblast growth factor receptor-5 preferentially expressed in the pancreas(1). Biochim. Biophys. Acta 1518, 152-156.
36. Kimura T., Suzuki H., Ohashi T., Asano K., Kiyota H. and Eto Y. (2001). The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 92, 2555-2561.
37. Knowles M.A. (2001). What we could do now: molecular pathology of bladder cancer. Mol. Pathol. 54, 215-221.
38. Knowles M.A. and Williamson M. (1993). Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Res. 53, 133-139.
39. Knowles M.A., Elder P.A., Williamson M., Cairns J.P., Shaw M.E. and Law M.G. (1994). Allelotype of human bladder cancer. Cancer Res. 54, 531-538.
40. Koksal I.T., Yasar D., Dirice E., Usta M.F., Karauzum S., Luleci G., Baykara M. and Sanlioglu S. (2005). Differential PTEN protein expression profiles in superficial versus invasive bladder cancers. Urol. Int. 75, 102-106.
41. Kurie J.M., Shin H.J., Lee J.S., Morice R.C., Ro J.Y., Lippman S.M., Hittelman W.N., Yu R., Lee J.J. and Hong W.K. (1996). Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin. Cancer Res. 2, 1787-1793.
42. L'Hote C.G. and Knowles M.A. (2005). Cell responses to GFGR3 signalling: growth, differentitation and apoptosis. Exp. Cell Res. 304, 417-431
43. Lee H.M., Takeyama K., Dabbagh K., Lausier J.A., Ueki I.F. and Nadel J.A. (2000). Agarose plug instillation causes goblet cell metaplasia by activating EGF receptors in rat airways. Am. J. Physiol. Lung Cell Mol. Physiol. 278, L185-L192.
44. Levesque P., Ramchurren N., Saini K., Joyce A., Libertino J. and Summerhayes I.C. (1993). Screening of human bladder tumors and urine sediments for the presence of H-ras mutations. Int. J. Cancer 55, 785-790.
45. Lipponen P. and Eskelinen M. (1994). Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br. J. Cancer 69, 1120-1125.
46. Lombardi D.P., Geradts J., Foley J.F., Chiao C., Lamb P.W. and Barrett J.C. (1999). Loss of KAI1 expression in the progression of colorectal cancer. Cancer Res. 59, 5724-5731.
47. Marreiros A., Czolij R., Yardley G., Crossley M. and Jackson P. (2003). Identification of regulatory regions within the KAI1 promoter: a role for binding of AP1, AP2 and p53. Gene 302, 155-164.
48. Mascia F., Mariani V., Girolomoni G. and Pastore S. (2003). Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am. J. Pathol. 163, 303-312.
49. Menard S., Casalini P., Campiglio M., Pupa S., Agresti R. and Tagliabue E. (2001). HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann. Oncol. 12 (Suppl 1), S15-S19.
50. Miao T.J., Wang Z. and Sang N. (1991). Correlation between the expression of the P21 ras oncogene product and the biological behavior of bladder tumors. Eur. Urol. 20, 307-310.
51. Moch H., Sauter G., Moore D., Mihatsch M.J., Gudat F. and Waldman F. (1993). p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer. Virchows Arch. (A). 423, 329-334.
52. Mostofi F.K. (1973). Histological typing of urinary bladder tumours. In: International histological classification of tumours. No. 10, Mostofi F.K., Sobin L.H. and Torloni H. (eds). World Health Organization. Geneva, Switzerland. p 17.
53. Odintsova E., Sugiura T. and Berditchevski F. (2000). Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/ KAI-1. Curr. Biol. 10, 1009-1012.
54. Odintsova E., Voortman J., Gilbert E. and Berditchevski F. (2003). Tetraspanin CD82 regulates compartmentalisation and ligand-induced dimerization of EGFR. J. Cell Sci. 116, 4557-4566.
55. Ow K., Delprado W., Fisher R., Barrett J., Yu Y., Jackson P. and Russell P.J. (2000). Relationship between expression of the KAI1 metastasis suppressor and other markers of advanced bladder cancer. J. Pathol. 191, 39-47.
56. Prenzel N., Fischer O.M., Streit S., Hart S. and Ullrich A. (2001). The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer 8, 11-31.
57. Press M.F., Cordon-Cardo C. and Slamon D.J. (1990). Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5, 953-962.
58. Ravery V., Grignon D., Angulo J., Pontes E., Montie J., Crissman J. and Chopin D. (1997). Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol. Res. 25, 9-17.
59. Reid S. and Ferretti P. (2003). Differential expression of fibroblast growth factor receptors in the developing murine choroid plexus. Brain Res. Dev. Brain Res. 141, 15-24.
60. Reilly J.F. and Maher P.A. (2001). Importin beta-mediated nuclear import of fibroblast growth factor receptor: role in cell proliferation. J. Cell Biol. 152, 1307-1312.
61. Rosen L.B. and Greenberg M.E. (1996). Stimulation of growth factor receptor signal transduction by activation of voltage-sensitive calcium channels. Proc. Natl. Acad. Sci. USA 93, 1113-1118.
62. Røtterud R., Nesland J.M., Berner Aa. and Fosså S.D. (2004). Expression of the epidermal growth factor receptor family in normal and malignant urothelium. (Submitted).
63. Rubin I. and Yarden Y. (2001). The basic biology of HER2. Ann. Oncol. 12 (Suppl 1), S3-S8.
64. Saito S., Hata M., Fukuyama R., Sakai K., Kudoh J., Tazaki H. and Shimizu N. (1997). Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. Int. J. Urol. 4, 178-185.
65. Sauter G., Moch H., Moore D., Carroll P., Kerschmann R., Chew K., Mihatsch M.J., Gudat F. and Waldman F. (1993). Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res. 53, 2199-2203.
66. Shaw M.E. and Knowles M.A. (1995). Deletion mapping of chromosome 11 in carcinoma of the bladder. Genes Chromosomes. Cancer 13, 1-8.
67. Shi W. and Zhang S. (1997). Expression of epidermal growth factor receptor in human duodenal ulcer. Hua Xi. Yi. Ke. Da. Xue. Xue. Bao. 28, 280-283.
68. Sibley K., Cuthbert-Heavens D. and Knowles M.A. (2001). Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell caminoma. Oncogene 20, 686-691.
69. Simpson L. and Parsons R. (2001). PTEN: life as a tumor suppressor. Exp. Cell Res. 264, 29-41.
70. Uchida S., Shimada Y., Watanabe G., Li Z.G., Hong T., Miyake M. and Imamura M. (1999). Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma. Br. J. Cancer 79, 1168-1173.
71. van Rhijn B.W., Montironi R., Zwarthoff E.C., Jobsis A.C. and Van der Kwast T.H. (2002). Frequent FGFR3 mutations in urothelial papilloma. J. Pathol. 198, 245-251.
72. van Velzen D., Krishnan K.R., Parsons K.F., Soni B.M., Fraser M.H. and Vaidyanathan S. (1996). Epidermal growth factor receptor in the vesical urothelium of paraplegic and tetraplegic patients: an immunohistochemical study. Spinal Cord 34, 578-586.
73. Viola M.V., Fromowitz F., Oravez S., Deb S. and Schlom J. (1985). ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma. J. Exp. Med. 161, 1213-1218.
74. White A., Lamb P.W. and Barrett J.C. (1998). Frequent downregulation of the KAI1(CD82) metastasis suppressor protein in human cancer cell lines. Oncogene 16, 3143-3149.
75. Wood D.-P.J., Fair W.R. and Chaganti R.S. (1992). Evaluation of epidermal growth factor receptor DNA amplification and mRNA expression in bladder cancer. J. Urol. 147, 274-277.
76. Wu X., Senechal K., Neshat M.S., Whang Y.E. and Sawyers C.L. (1998). The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA 95, 15587-15591.
77. Ye D.W., Zheng J.F., Qian S.X. and Ma Y.J. (1993). Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors. Urol. Res. 21, 39-43.
78. Yu Y., Yang J.L., Markovic B., Jackson P., Yardley G., Barrett J. and Russell P.J. (1997). Loss of KAI1 messenger RNA expression in both high-grade and invasive human bladder cancers. Clin. Cancer Res. 3, 1045-1049.
79. Zammit C., Barnard R., Gomm J., Coope R., Shousha S., Coombes C. and Johnston C. (2001). Altered intracellular localization of fibroblast growth factor receptor 3 in human breast cancer. J. Pathol. 194, 27-34.
80. Zhang X.A., He B., Zhou B. and Liu L. (2003). Requirement of the p130CAS-Crk coupling for metastasis suppressor KAI1/CD82-mediated inhibition of cell migration. J. Biol. Chem. 278, 27319-27328.